Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α-Gal epitope (Galα1,3Galα1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.

The presently-disclosed subject matter relates to compositions of dual layer encapsulated cells, dual layer encapsulated stem cells. The presently-disclosed subject matter further relates to methods for improving retention of cells in vivo at a site of injury.

The presently-disclosed subject matter relates to compositions of dual layer encapsulated cells, dual layer encapsulated stem cells. The presently-disclosed subject matter further relates to methods for improving retention of cells in vivo at a site of injury.

The purpose of the present invention is to provide: detergent-free decellularization method of xenogenic biological tissues for human body surgery, in which the pericardium, blood vessels, other membrane-like biological tissues, and the like are decellularized so as to have resistance to mechanical property loss, mineralization and immune reactivity; and decellularized tissue. Decellularized tissue, according to the present invention, when compared to untreated tissue, has greater calcification reduction in vivo, blood compatibility and biocompatibility improvement, tissue thickness reduction, and increases in tensile strength, kink resistance and the like.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.

The present invention provides a tissue-engineering vascular graft (TEVG) comprising a biodegradable scaffold, and a plurality of stem cell-derived vascular smooth muscle cells (VSMCs), wherein the plurality of stem cell-derived VSMCs are seeded on the biodegradable synthetic polymer scaffold and are cultured under mechanical and biochemical stimulation.

The present invention provides a tissue-engineering vascular graft (TEVG) comprising a biodegradable scaffold, and a plurality of stem cell-derived vascular smooth muscle cells (VSMCs), wherein the plurality of stem cell-derived VSMCs are seeded on the biodegradable synthetic polymer scaffold and are cultured under mechanical and biochemical stimulation.

Provided is a cell structure including: a connective tissue structure; and an epithelial structure placed on the connective tissue structure, in which the connective tissue structure contains a fragmented extracellular matrix component and first cells including mesenchymal cells, at least a part of the fragmented extracellular matrix component is placed between the first cells, and the epithelial structure contains epithelial cells.